Journal
Counterfeits, Research Peptides and the Grey Market: How to Stay Inside the System
As legal compounding narrows, the unapproved market grows. The distinctions matter more than they ever have.
There are three markets, not two. Approved products, lawfully compounded preparations, and an unapproved grey market of research peptides and counterfeits with no prescriber, no pharmacy licence and no recourse. As the compounding pathway narrows, the third market grows — and it is the only one with no floor at all.
The three markets
Approved products. Reviewed by the FDA for safety, effectiveness and manufacturing quality. Supplied through licensed pharmacies against a prescription. Recourse exists at every level.
Lawfully compounded preparations. Prepared by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, against a prescription. Not FDA-approved and not reviewed for safety or effectiveness — but inside the regulatory system, with a licensed pharmacy and an identifiable prescriber.
The grey market. Peptides sold as research chemicals, products shipped from unregulated sources, counterfeits. No prescriber, no pharmacy licence, no testing you can verify, no recourse. Not a cheaper version of the second category — a different thing entirely.
Why the third market is growing now
Supply pressure. The FDA has proposed excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list, with comments closing 30 July 2026, and both shortage listings have been resolved. Patients whose supply is disrupted look for alternatives, and the grey market advertises to exactly that moment.
Investigational compounds amplify it. Retatrutide and CagriSema are unapproved, generate enormous search interest, and are widely sold by vendors who describe them as research chemicals. Phase 3 figures for retatrutide circulate online sourced largely to those vendors, which is why we have declined to publish one.
What the risks actually are
Not vague. Novo Nordisk litigation has alleged that some compounded semaglutide contained impurities at substantial levels — an allegation in active litigation rather than an established finding, and we report it as such. The FDA has documented adverse events involving compounded GLP-1s including dosing errors requiring hospitalisation. Neither of those concerns the grey market, which is less regulated still.
Salt forms are a specific and checkable issue. Semaglutide sodium and semaglutide acetate are different substances from the semaglutide base in approved products, and the FDA has stated they are not appropriate for compounding. A product sold as one of the salt forms is not the approved molecule.
How to tell which market you are in
- Is there a named prescriber holding a current state licence? Check the medical board. No prescriber means no legitimate route.
- Is there a named pharmacy holding a current licence? Check the pharmacy board.
- Does the seller use the phrase "research use only" or "not for human consumption"? That is a complete answer.
- Is the product one that exists as an approved or lawfully compounded item? Retatrutide and CagriSema do not.
- Can you get a certificate of analysis tied to your batch number?
The cheaper option that is actually cheaper
The grey market's pitch is price. That pitch has weakened substantially: brand Zepbound is $299 direct from LillyDirect, approved orals start at $149, Medicare's Bridge programme is $50 for eligible enrollees, and commercial coverage can bring either brand near $25.
Within lawful compounding, published flat-rate programmes run from around $147 to $215 a month with pricing stated openly before intake. Whatever the argument for stepping outside the system, in 2026 it is not a strong cost argument.
If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.
| Market | Prescriber | Licensed pharmacy | FDA review | Recourse |
|---|---|---|---|---|
| Approved products | yes | yes | yes | Full |
| Lawfully compounded | yes | yes | no | Pharmacy board and prescriber |
| Grey market / research peptides | no | no | no | None |
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Is there a named prescriber with a current state licence? | Check the medical board, not the seller. |
| 2 | Is there a named pharmacy with a current licence? | Check the pharmacy board. |
| 3 | Does the seller say research use only? | That is a complete answer. |
| 4 | Does this product exist as an approved or compounded item? | Retatrutide and CagriSema do not. |
| 5 | Can you get a certificate of analysis for your batch? | Matched to the batch number on your vial. |
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
Questions readers actually ask
Are research peptides a legal way to get GLP-1s?
No. Products sold for research use are outside the approved and compounded supply chains, with no prescriber, no pharmacy licence and no recourse.
How do I know if a source is legitimate?
A named prescriber with a current state licence and a named pharmacy with a current licence. Check both with the issuing boards, not with the seller.
What is the salt form issue?
Semaglutide sodium and acetate are different substances from the semaglutide base in approved products. The FDA has said they are not appropriate for compounding.
Related on this site
- The journalJournal
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- FDA Compounded GLP-1 Rules in 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- SURPASS-2: Tirzepatide vs Semaglutide in Type 2 DiabetesResearch
- SURMOUNT-OSA and Tirzepatide for Sleep ApneaResearch
- SURMOUNT-5: Tirzepatide vs Semaglutide Head to HeadResearch
GLP-1 Tirzepatide Review. “Counterfeits, Research Peptides and the Grey Market: How to Stay Inside the System.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/journal/glp1-supply-chain-counterfeits/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.